Found: 150
Select item for more details and to access through your institution.
Innovative vaccine approaches—a Keystone Symposia report.
- Published in:
- Annals of the New York Academy of Sciences, 2022, v. 1511, n. 1, p. 59, doi. 10.1111/nyas.14739
- By:
- Publication type:
- Article
A controlled effects approach to assessing immune correlates of protection.
- Published in:
- Biostatistics, 2023, v. 24, n. 4, p. 850, doi. 10.1093/biostatistics/kxac024
- By:
- Publication type:
- Article
Evaluation of treatment effect modification by biomarkers measured pre- and post-randomization in the presence of non-monotone missingness.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Inference on treatment effect modification by biomarker response in a three-phase sampling design.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Statistical methods for down-selection of treatment regimens based on multiple endpoints, with application to HIV vaccine trials.
- Published in:
- 2017
- By:
- Publication type:
- journal article
A joint model for mixed and truncated longitudinal data and survival data, with application to HIV vaccine studies.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Evaluating principal surrogate endpoints with time-to-event data accounting for time-varying treatment efficacy.
- Published in:
- Biostatistics, 2014, v. 15, n. 2, p. 251, doi. 10.1093/biostatistics/kxt055
- By:
- Publication type:
- Article
Case-only method for cause-specific hazards models with application to assessing differential vaccine efficacy by viral and host genetics.
- Published in:
- Biostatistics, 2014, v. 15, n. 1, p. 196, doi. 10.1093/biostatistics/kxt018
- By:
- Publication type:
- Article
Mark-specific proportional hazards model with multivariate continuous marks and its application to HIV vaccine efficacy trials.
- Published in:
- Biostatistics, 2013, v. 14, n. 1, p. 60, doi. 10.1093/biostatistics/kxs022
- By:
- Publication type:
- Article
Semiparametric estimation of the average causal effect of treatment on an outcome measured after a postrandomization event, with missing outcome data.
- Published in:
- Biostatistics, 2010, v. 11, n. 1, p. 34, doi. 10.1093/biostatistics/kxp034
- By:
- Publication type:
- Article
The 2-sample problem for failure rates depending on a continuous mark: an application to vaccine efficacy.
- Published in:
- Biostatistics, 2008, v. 9, n. 2, p. 263
- By:
- Publication type:
- Article
Failure time analysis of HIV vaccine effects on viral load and antiretroviral therapy initiation.
- Published in:
- Biostatistics, 2005, v. 6, n. 3, p. 374, doi. 10.1093/biostatistics/kxi014
- By:
- Publication type:
- Article
Maximum likelihood estimation in semiparametric selection bias models with application to AIDS vaccine trials.
- Published in:
- Biometrika, 1999, v. 86, n. 1, p. 27, doi. 10.1093/biomet/86.1.27
- By:
- Publication type:
- Article
Antibody Correlates of Protection From Severe Respiratory Syncytial Virus Disease in a Vaccine Efficacy Trial.
- Published in:
- Open Forum Infectious Diseases, 2023, v. 10, n. 1, p. 1, doi. 10.1093/ofid/ofac693
- By:
- Publication type:
- Article
Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-03154-6
- By:
- Publication type:
- Article
Correlates of Protection, Thresholds of Protection, and Immunobridging among Persons with SARS-CoV-2 Infection.
- Published in:
- Emerging Infectious Diseases, 2023, v. 29, n. 2, p. 381, doi. 10.3201/eid2902.221422
- By:
- Publication type:
- Article
Virologic and Regimen Termination Surrogate End Points in AIDS Clinical Trials.
- Published in:
- JAMA: Journal of the American Medical Association, 2001, v. 285, n. 6, p. 777, doi. 10.1001/jama.285.6.777
- By:
- Publication type:
- Article
Methods for comparing durability of immune responses between vaccine regimens in early-phase trials.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Finite-sample corrected generalized estimating equation of population average treatment effects in stepped wedge cluster randomized trials.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Endpoints in vaccine trials.
- Published in:
- 2004
- By:
- Publication type:
- journal article
HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial.
- Published in:
- 2014
- By:
- Publication type:
- journal article
FCCR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial.
- Published in:
- Journal of Clinical Investigation, 2014, v. 124, n. 9, p. 3879, doi. 10.1172/JCI75539
- By:
- Publication type:
- Article
Rapidly identifying new coronavirus mutations of potential concern in the Omicron variant using an unsupervised learning strategy.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-23342-2
- By:
- Publication type:
- Article
Immunobridging efficacy of a tetravalent dengue vaccine against dengue and against hospitalized dengue from children/adolescents to adults in highly endemic countries.
- Published in:
- Transactions of the Royal Society of Tropical Medicine & Hygiene, 2021, v. 115, n. 7, p. 750, doi. 10.1093/trstmh/traa154
- By:
- Publication type:
- Article
Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial.
- Published in:
- Nature Medicine, 2011, v. 17, n. 3, p. 366, doi. 10.1038/nm.2316
- By:
- Publication type:
- Article
Effects of HIV-1 Serostatus, HIV-1 RNA Concentration, and CD4 Cell Count on the Incidence of Malaria Infection in a Cohort of Adults in Rural Malawi.
- Published in:
- Journal of Infectious Diseases, 2005, v. 192, n. 6, p. 984
- By:
- Publication type:
- Article
HIV-1 Virologic and Immunologic Progression and Initiation of Antiretroviral Therapy among HIV-1--Infected Subjects in a Trial of the Efficacy of Recombinant Glycoprotein 120 Vaccine.
- Published in:
- Journal of Infectious Diseases, 2005, v. 192, n. 6, p. 974, doi. 10.1086/432734
- By:
- Publication type:
- Article
Correlation between Immunologic Responses to a Recombinant Glycoprotein 120 Vaccine and Incidence of HIV-1 Infection in a Phase 3 HIV-1 Preventive Vaccine Trial.
- Published in:
- Journal of Infectious Diseases, 2005, v. 191, n. 5, p. 666, doi. 10.1086/428405
- By:
- Publication type:
- Article
Breakthrough Infections during Phase 1 and 2 Prime-Boost HIV-1 Vaccine Trials with Canarypox Vectors (ALVAC) and Booster Dose of Recombinant gp120 or gp160.
- Published in:
- Journal of Infectious Diseases, 2004, v. 190, n. 5, p. 903, doi. 10.1086/423284
- By:
- Publication type:
- Article
What Constitutes Efficacy for a Human Immunodeficiency Virus Vaccine that Ameliorates Viremia: Issues Involving Surrogate End Points in Phase 3 Trials.
- Published in:
- Journal of Infectious Diseases, 2003, v. 188, n. 2, p. 179, doi. 10.1086/376449
- By:
- Publication type:
- Article
HAI and NAI titer correlates of inactivated and live attenuated influenza vaccine efficacy.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Super LeArner Prediction of NAb Panels (SLAPNAP): a containerized tool for predicting combination monoclonal broadly neutralizing antibody sensitivity.
- Published in:
- Bioinformatics, 2021, v. 37, n. 22, p. 4187, doi. 10.1093/bioinformatics/btab398
- By:
- Publication type:
- Article
Semiparametric estimation of treatment effects given base-line covariates on an outcome measured after a post-randomization event occurs.
- Published in:
- Journal of the Royal Statistical Society: Series B (Statistical Methodology), 2007, v. 69, n. 5, p. 879, doi. 10.1111/j.1467-9868.2007.00615.x
- By:
- Publication type:
- Article
Author Correction: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-43384-y
- By:
- Publication type:
- Article
Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men.
- Published in:
- PLoS ONE, 2015, v. 10, n. 9, p. 1, doi. 10.1371/journal.pone.0137666
- By:
- Publication type:
- Article
Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial Reveals an Association of Nonspecific Interferon-γ Secretion with Increased HIV-1 Infection Risk: A Cohort-Based Modeling Study.
- Published in:
- PLoS ONE, 2014, v. 9, n. 11, p. 1, doi. 10.1371/journal.pone.0108631
- By:
- Publication type:
- Article
Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection.
- Published in:
- PLoS ONE, 2014, v. 9, n. 2, p. 1, doi. 10.1371/journal.pone.0087572
- By:
- Publication type:
- Article
A semiparametric Cox–Aalen transformation model with censored data.
- Published in:
- Biometrics, 2023, v. 79, n. 4, p. 3111, doi. 10.1111/biom.13895
- By:
- Publication type:
- Article
Nonparametric estimation of the causal effect of a stochastic threshold‐based intervention.
- Published in:
- Biometrics, 2023, v. 79, n. 2, p. 1014, doi. 10.1111/biom.13690
- By:
- Publication type:
- Article
Semiparametric additive time‐varying coefficients model for longitudinal data with censored time origin.
- Published in:
- Biometrics, 2023, v. 79, n. 2, p. 695, doi. 10.1111/biom.13610
- By:
- Publication type:
- Article
Efficient nonparametric inference on the effects of stochastic interventions under two‐phase sampling, with applications to vaccine efficacy trials.
- Published in:
- Biometrics, 2021, v. 77, n. 4, p. 1241, doi. 10.1111/biom.13375
- By:
- Publication type:
- Article
Nonparametric variable importance assessment using machine learning techniques.
- Published in:
- Biometrics, 2021, v. 77, n. 1, p. 9, doi. 10.1111/biom.13392
- By:
- Publication type:
- Article
Rejoinder to "Nonparametric variable importance assessment using machine learning techniques".
- Published in:
- Biometrics, 2021, v. 77, n. 1, p. 28, doi. 10.1111/biom.13389
- By:
- Publication type:
- Article
Estimation of the optimal surrogate based on a randomized trial.
- Published in:
- Biometrics, 2018, v. 74, n. 4, p. 1271, doi. 10.1111/biom.12879
- By:
- Publication type:
- Article
Model-robust inference for continuous threshold regression models.
- Published in:
- Biometrics, 2017, v. 73, n. 2, p. 452, doi. 10.1111/biom.12623
- By:
- Publication type:
- Article
Generalized semiparametric varying-coefficient model for longitudinal data with applications to adaptive treatment randomizations.
- Published in:
- Biometrics, 2017, v. 73, n. 2, p. 441, doi. 10.1111/biom.12626
- By:
- Publication type:
- Article
Design and Estimation for Evaluating Principal Surrogate Markers in Vaccine Trials.
- Published in:
- Biometrics, 2013, v. 69, n. 2, p. 301, doi. 10.1111/biom.12014
- By:
- Publication type:
- Article
Rejoinder to 'A Note on Two-Sample Tests for Comparing Intra-Individual Genetic Sequence Diversity Between Populations'.
- Published in:
- Biometrics, 2012, v. 68, n. 4, p. 1326, doi. 10.1111/j.1541-0420.2012.01776.x
- By:
- Publication type:
- Article
Assessing Treatment-Selection Markers using a Potential Outcomes Framework.
- Published in:
- Biometrics, 2012, v. 68, n. 3, p. 687, doi. 10.1111/j.1541-0420.2011.01722.x
- By:
- Publication type:
- Article